10-Q · May 6, 2026
Mineralys Therapeutics reported a net loss of $39.3 million for Q1 2026 with an EPS of $(0.47), missing consensus estimates of $(0.45). The company indicated a strong cash position of $646.1 million, which they project…
Earnings analysis · 10-Q
MLYS earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Mineralys remains a pre-revenue biotechnology company, with diluted EPS of -$2.85 versus -$0.47 in Q1 2026 and -$0.66 in Q2 2025, while Q2 net loss increased to $241.1 million from $43.3 million primarily because of the…
Read full summary
Mineralys remains a pre-revenue biotechnology company, with diluted EPS of -$2.85 versus -$0.47 in Q1 2026 and -$0.66 in Q2 2025, while Q2 net loss increased to $241.1 million from $43.3 million primarily because of the $200.0 million Tanabe payment. Liquidity is comparatively strong at $661.4 million, supplemented by a $100.0 million secured term loan and additional financing capacity, but the company faces substantial launch spending, up to $265.0 million of remaining Tanabe-related obligations, and debt terms tied to FDA approval. The December 22, 2026 PDUFA date remains the key catalyst, but the severe EPS miss and increased financial obligations support a bearish trend assessment.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-2.85
What stood out
-
EPS deteriorated sharply
Diluted EPS was -$2.85, down from -$0.47 in Q1 2026 and -$0.66 in Q2 2025. The result was also below the -$0.54 consensus estimate.
-
Pre-revenue profile persists
The company has never generated revenue and reported no product sales; revenue remains effectively $0 until potential regulatory approval of lorundrostat.
-
Liquidity supports near-term launch plans
Cash, cash equivalents and investments totaled $661.4 million as of June 30, 2026. Management believes this amount can fund planned operations, including a potential commercial launch, for at least twelve months.
-
Regulatory milestone remains on track
The FDA accepted the lorundrostat NDA and assigned a PDUFA target date of December 22, 2026. The company has completed six lorundrostat clinical trials, including the pivotal Launch-HTN and Phase 2 Advance-HTN trials.
-
Debt financing expanded liquidity
A $100.0 million Tranche A senior secured term loan was drawn on June 2, 2026, while up to $400.0 million of additional term loans remained available subject to conditions as of June 30, 2026.
-
Operating cash burn modestly improved
Six-month operating cash use improved modestly to $72.0 million from $75.7 million in the prior-year period, a $3.6 million improvement, despite continued development and commercial-readiness spending.
What to watch
-
Large Tanabe payment inflated losses
Q2 2026 net loss was $241.1 million versus $43.3 million in Q2 2025, an increase of $197.8 million. The increase primarily reflected the $200.0 million upfront payment to Tanabe and higher corporate expenses.
-
Substantial future milestone obligations
The Fourth Amendment requires up to $255.0 million of remaining commercial milestone payments to Tanabe, plus up to $10.0 million related to commercialization for a potential second indication.
-
New secured debt raises financial risk
The company borrowed $100.0 million under a loan bearing interest at three-month SOFR plus 5.50%; the effective interest rate was 9.91% as of June 30, 2026. The loan is secured by substantially all assets, including intellectual property.
-
Debt terms depend on FDA approval
The Loan Agreement permits acceleration of the maturity date to June 30, 2028 if FDA approval of the lorundrostat NDA is not obtained by September 30, 2027. It also requires repayment of all term loans in four equal installments beginning September 30, 2027 if the approval condition is not met by that date.
-
Pre-launch spending is accelerating
Management expects research and development and general and administrative expenses to increase substantially for regulatory activities, commercial-readiness hiring, market access, manufacturing, and a potential launch. Q2 R&D expense was $221.4 million versus $38.3 million in Q2 2025.
-
OSA development opportunity weakened
The Explore-OSA trial did not demonstrate a clinically meaningful difference versus placebo on its primary apnea-hypopnea index endpoint after four weeks, although lorundrostat produced an 11.1 mmHg blood-pressure reduction versus 1.0 mmHg for placebo in the pre-planned parallel-arm analysis.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and investments of $661.4 million as of June 30, 2026 are expected to fund planned operations, including a potential commercial launch of lorundrostat, for at least twelve months. The lorundrostat NDA retains a PDUFA target date of December 22, 2026.
Earlier filings 4
10-K · March 12, 2026
Mineralys is a clinical‑stage, pre‑revenue biopharma concentrated on a single product candidate, lorundrostat, for aldosterone‑driven cardiorenal diseases. The company submitted an NDA in December 2025 that the FDA…
10-Q · November 10, 2025
Mineralys reported a narrower net loss in Q3 2025 of $(36,932)k (EPS $(0.52)) versus $(56,342)k (EPS $(1.13)) in Q3 2024, driven by lower operating expenses and higher interest income. The company completed multiple…
10-K · February 12, 2025
Mineralys (MLYS) is a clinical‑stage biotech focused solely on lorundrostat, an oral, selective aldosterone synthase inhibitor. The 10‑K reports completion of randomization for two pivotal trials (Advance‑HTN: 285…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.